1. Scrip
  2. >>Archive

Cell Therapeutics names new board member

 
• By Lucie Ellis-Taitt

Seattle, US-based Cell Therapeutics, a biopharmaceutical company developing a portfolio of oncology products, has named Karen Ignagni to its board of directors – effective from 3 February 2014. Ms Ignagni currently serves as president and CEO of America's Health Insurance Plans (AHIP), the trade association representing US health plans. She also currently sits on the boards of the National Quality Forum, the National Advisory Committee for Altarum Institute's Center for Sustainable Health Spending, and the Healthcare Financial Management Association's Leadership Council.

Seattle, US-based Cell Therapeutics, a biopharmaceutical company developing a portfolio of oncology products, has named Karen Ignagni to its board of directors – effective from 3 February 2014. Ms Ignagni currently serves as president and CEO of America's Health Insurance Plans (AHIP), the trade association representing US health plans. She also currently sits on the boards of the National Quality Forum, the National Advisory Committee for Altarum Institute's Center for Sustainable Health Spending, and the Healthcare Financial Management Association's Leadership Council.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.